Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia

Future Lipidology

Volumn 4, Issue 3, 2009, Pages 291-302

  Budinski, Dragos ^a   Arneson, Valerie ^b   Hounslow, Neil ^a   Gratsiansky, Nikolai ^c  

^a Kowa Research Europe Ltd   (United Kingdom)

^b PharmaNet Ltd   (United Kingdom)

^c FEDERAL RESEARCH AND CLINICAL CENTER OF PHYSICAL CHEMICAL MEDICINE OF FEDERAL MEDICAL BIOLOGICAL AGENCY   (Russian Federation)

Author keywords

Atorvastatin; Dyslipidemia; Hypercholesterolemia; Lipids; Pitavastatin; Statin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PITAVASTATIN; PLACEBO; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; FURUNCULOSIS; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; INFESTATION; INSOMNIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIGRAINE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 67249088838     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.20     Document Type: Article

References (48)

1. Fonesca F, Ruiz A, Cardona-Muñoz E: The DISCOVERY PENTA study: a Direct Statin Comparison of LDL-C Value - an Evaluation of Rosuvastatin Therapy Compared with Atorvastatin. Curr. Med. Res. Opin. 21(8), 1307-1315 (2005).
2. McKenney J, Jones P, Adamczyk M et al.: Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr. Med. Res. Opin. 19(9), 689-698 (2003).
3. Meyer J, Schultz J, O'Donnell J, Patel P, Sasane R: Patterns and effectiveness of lipid-lowering therapies in a managed care environment. Value Health. 8, 601-612 (2005).
4. Foley K, Simpson R Jr, Crouse J 3rd et al.: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am. J. Cardiol. 92, 79-81 (2003).
5. Schuster H: Improving lipid management - to titrate, combine or switch. Int. J. Clin. Pract. 58(7), 689-694 (2004).
6. Pearson T, Laurora I, Chu H, Kafoneck S: The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low density lipoprotein cholesterol goals. Arch. Intern. Med. 160, 459-467 (2000).
7. Liberopoulos E, Florentin M, Mikhailidis D, Elisaf M: Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin. Drug Saf. 7(6),717-725 (2008).
8. Bortorff C, Houri J, Natarbartolo A et al.: Statin safety: what to know. Am. J. Geriatr. Cardiol. 13(3 Suppl. 1),34-38 (2004).
9. de Lemos J, Blazing M, Wiviott S et al.: Early intensive vs delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292(11), 1307-1316 (2004).
10. Waters D: Safety of high-dose atorvastatin therapy. Am. J. Cardiol. 96(5A), F69-F75 (2005).
11. Shitara Y, Sato H, Sugiyama Y: Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45, 689-723 (2005).
12. Rutishauser J: The role of statins in clinical medicine - LDL-cholesterol lowering and beyond. Swiss Med. Wkly 136(3-4),41-49 (2006).
13. Ansell B: Not getting to goal: the clinical costs of noncompliance. J. Manag. Care Pharm. 14(Suppl. 6B), 9-15 (2008).
14. Watson K: What is the evidence in favor of low-dose statin therapy in 2008? Curr. Atheroscler. Rep. 10(1),33-38 (2008).
15. Murphy M, Wei L, Watson A, MacDonald T: 'Real-life' reduction in cholesterol with statins, 1993 to 2002. Br. J. Clin. Pharmacol. 65(4), 587-592 (2008).
16. Stein E: Managing dyslipidemia in the high-risk patient. Am. J. Cardiol. 89, C50-C57 (2002).
17. Isley W: Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs Today 37, 587-594 (2001).
18. Hayashi T, Yokote K, Saito Y, Iguchi A: Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin. Pharmacother. 8, 2315-2327 (2007).
19. Fujino H, Yamada I, Kojima J et al.: Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and humans. Xenobio. Metabol. Dispos. 14, 415-424 (1999).
20. Fuijno H, Saito T, Tsunenari Y, Kojima J: Interaction between several medicines and statins. Arzneimittelforschung 53(3), 145-153 (2003).
21. Sakaeda T, Fujino H, Komoto C: Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1 mediated transport. Pharm. Res. 23, 506-512 (2006).
22. Hirano M, Maeda K, Shitara Y: Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34, 1229-1236 (2006).
23. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106, 3143-3421 (2002).
24. European Atherosclerosis Society: The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur. Heart J. 9, 571-600 (1988).
25. Noji Y, Higashikata T, Inazu A et al.: Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163, 157-164 (2002).
26. Kajinami K, Koizumi J, Ueda K et al.: Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia: Hokuriku NK-104 Study Group. Am. J. Cardiol. 85, 178-183 (2000).
27. Strandberg T, Feely J, Sigurdsson E: Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin. Ther. 26(11), 1821-1833 (2004).
28. Yoshitomi Y, Ishii T, Kaneki M et al.: Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. J. Atheroscler. Thromb. 13(2), 108-113 (2006).
29. Park S, Kang H-J, Rim S-J: A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin. Ther. 27, 1074-1082 (2005).
30. Friedewald W, Levy D, Fredrickson D: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the preparative ultracentrifuge. Clin. Chem. 18, 499-502 (1972).
31. LaRosa J, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled studies. JAMA 282, 2340-2346 (1999).
32. Heart Protection Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled study. Lancet 360(9326), 7-22 (2002).
33. Sasaki J, Ikeda Y, Kuribayashi T et al.: A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin. Ther. 30, 1089-1101 (2008).
34. Grigioni F, Carigi S, Potena L et al.: Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. Transplant Proc. 38(5), 1507-1510 (2006).
35. Versmissen J, Oosterveer D, Yazdanpanah M et al.: Efficacy of statins in familial hypercholesterolemia: a long-term cohort study. BMJ 337, a2423 (2008).
36. Ratz Bravo A, Tchambaz L, Krähenbühl-Melcher A et al.: Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf. 28(3),263-275 (2005).
37. Sanossian N, Ovbiagele B: Drug insight: translating evidence on statin therapy into clinical benefits. Nat. Clin. Pract. Neurol. 4(1),42-49 (2008).
38. Colleran K, Richards A, Shafer K: Disparities in cardiovascular disease risk and treatment: demographic comparison. J. Investig. Med. 55(8),415-422 (2007).
39. Jacobson T: Overcoming 'ageism' bias in the treatment of hypercholesterolemia: a review of safety issues with statins in the elderly. Drug Saf. 29(5),421-448 (2006).
40. Gotto A: Statin therapy and the elderly: SAGE advice? Circulation 115, 681-683 (2007).
41. Cauley J, McTiernan A, Roadbough R et al.: Statin use and breast cancer: prospective results from the Women's Health Initiative. J. Natl Cancer Inst. 98(10),700-707 (2006).
42. Kurihara Y, Douzono T, Kawakita K, Nagasaka Y: A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (Livalor® Tablet): LIVALO Effectiveness and Safety (LIVES) Study. Jpn Pharmacol. Ther. 36(8),709-731 (2008).
43. Joint Formulary Committee: British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 50,135 (2005).
44. Jones P, Davidson M, Stein E et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am. J. Cardiol. 92, 152-160 (2003).
45. Brown B, Stukovsky K, Zhao X: Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr. Opin. Lipidol. 17, 631-636 (2006).
46. Cardenas G, Lavie C, Cardenas V, Milani R, McCullough P: The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev. Cardiovasc. Med. 9(4),239-258 (2008).
47. Eypasch E, Lefering R, Kum CK, Troidl H: Probability of adverse events that have not yet occurred: a statistical reminder. BMJ 311, 619-620 (1995).
48. Black D, Bakker-Arkema R, Nawrocki J: An overview of the clinical safety profile of atorvastatin (Lipitor™), a new HMG-CoA reductase inhibitor Arch. Intern. Med. 158, 577-584 (1998).